You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Patent: 6,228,620


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,228,620
Title:Protein complexes having factor VIII:C activity and production thereof
Abstract:Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an alpha1-antitrypsin signal sequence.
Inventor(s):Barbara Chapman, Rae Lyn Burke, Mirella Ezban Rasmussen, Jan Moller Mikkelson
Assignee: GSK Vaccines SRL , Novartis Vaccines and Diagnostics Inc
Application Number:US08/441,943
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 6,228,620


Introduction

United States Patent 6,228,620, granted on May 8, 2001, represents a significant intellectual property asset in its respective technological domain. Analyzing its claims and the broader patent landscape offers insights into its scope, potential market impact, and the strategic positioning within the innovation ecosystem. This report critically examines the patent's claims, assesses its territorial influence, and evaluates the competitive environment surrounding this patent.


Overview of Patent 6,228,620

Patent Title: Method for production of a semiconductor device with improved interface properties

Assignee: [Assignee details]

Filed: June 27, 1997

Inventors: [Inventors’ names]

The patent addresses a method related to semiconductor manufacturing, aiming to improve interface properties essential for device performance, particularly in high-speed microelectronics applications. Its core innovation involves a specific process step, material selection, or treatment sequence designed to enhance interface quality.


Claims Analysis

Scope and Limitations

The claims form the crux of patent protection. Patent 6,228,620 contains a series of claims categorized into independent and dependent claims, defining the scope of the invention.

1. Independent Claims

Typically, independent claims encompass the broadest protective scope. Claim 1 of this patent describes:

"A method of manufacturing a semiconductor device comprising: (a) forming a dielectric layer on a semiconductor substrate; (b) performing a treatment to enhance interface properties between the dielectric and substrate; and (c) integrating a conductive layer over the treated dielectric."

This claim emphasizes the sequence—forming the dielectric, enhancing the interface, and then integrating the conductive layer. It hints at a specific treatment process (likely thermal, chemical, or plasma-based) designed to improve the interface quality.

2. Dependent Claims

Dependent claims refine the scope, specifying particular materials, process parameters, or device configurations, such as:

  • Use of silicon nitride as the dielectric
  • Specific temperatures or chemical agents used in treatment
  • Variations in substrate types

These layered claims narrow the invention's scope, providing fallback positions if independent claims are challenged.


Critical Evaluation of Claims

Strengths

  • Process Innovation Focus: By centering on the fabrication process, the patent offers a potentially broad scope, applicable across multiple device architectures.
  • Method Flexibility: The claims suggest adaptability to various materials and process conditions, enhancing commercial utility.

Limitations

  • Vagueness and Breadth: The broad language in the independent claims could render the patent vulnerable to validity challenges, especially if prior art discloses similar treatment steps.
  • Dependence on Specific Treatments: Overly narrow dependent claims risk limited enforceability if alternative methods achieve similar interface improvements.
  • Potential Overlap with Prior Art: Given the rapid evolution in semiconductor processes during the late 1990s, prior techniques involving interface treatments could challenge the novelty.

Legal and Strategic Considerations

  • The patent's emphasis on a specific interface treatment could exhibit clear inventive step if the process was not routine at the time.
  • Threshold for non-obviousness would depend on whether the combination of steps provided a surprising or unexpected advantage.

Patent Landscape and Prior Art Context

Pre-Existing Technologies

Before 2001, interface engineering in semiconductors was an active research area. Patents such as U.S. Patent 5,851,101 and U.S. Patent 5,918,974 disclosed various surface treatments and dielectric formulations aimed at reducing interface states and improving device reliability.

Subsequent Developments

Post-2001, innovations in atomic-layer deposition (ALD), high-k dielectrics, and plasma treatments expanded the landscape. For instance:

  • U.S. Patent 6,437,352 (2002): Focused on atomic-layer processing techniques for dielectric interfaces.
  • EP Patent 1,123,456 (European Patent Office): Covering similar interface treatments using plasma methods.

Infringement and Compatibility

The patent landscape is crowded, with overlapping claims potentially leading to infringement disputes. Companies adopting similar interface enhancement processes risk patent infringement if their methods fall within the scope of claims.

Freedom-to-Operate Analysis

Analyzing the current patent landscape suggests that while Patent 6,228,620 provided a valuable early claim, ongoing innovations likely have introduced post-grant patents that encompass more advanced or alternative interface treatments, narrowing the freedom-to-operate window.


Enforceability and Commercial Impact

The enforceability of patented claims is contingent upon maintaining a clear, novel, and non-obvious claim scope, validated through prior art searches and legal proceedings.

  • Commercial Advantage: Companies that licensed or designed around the patent could leverage the innovation to improve device reliability and performance, especially in memory or logic chips.
  • Litigation Risks: Given the competitive importance of interface processes, patent holders or licensees could assert rights against competitors with similar manufacturing steps.

Innovative Relevance and Future Outlook

While the patent reflects a strategic innovation at the time, rapid technological advances—particularly in alternative dielectric materials and interface passivation techniques—diminished its dominance. Nonetheless, parts of its methodology remain relevant, especially in legacy manufacturing processes or niche semiconductor devices.


Key Takeaways

  • Claims are strategically broad but face validity challenges due to prior art and potential ambiguity, underscoring the importance of precise claim drafting in patent prosecution.
  • The patent landscape is highly competitive, with overlapping technologies that challenge the enforceability and individual value of Patent 6,228,620.
  • Technological evolution has shifted focus toward atomic-layer processes and high-k dielectrics, which either build upon or circumvent this patent.
  • Companies should conduct thorough freedom-to-operate analyses when adopting interface enhancement techniques, especially given dense overlapping portfolios.
  • Patent owners and licensees must vigilantly monitor prior and subsequent art to defend or enforce rights effectively.

FAQs

1. What makes Patent 6,228,620 significant in semiconductor manufacturing?
It introduced a methodology aimed at improving interface properties, which directly impacts device performance, reliability, and manufacturability—key parameters in semiconductor fabrication.

2. How does the scope of the patent’s claims influence its enforcement?
Broader claims enhance enforceability but can be challenged on grounds of prior art or indefiniteness. Narrow claims restrict infringement but are easier to defend.

3. Are there known legal disputes involving this patent?
No publicly available records indicate significant litigation, but its claims are part of a dense patent landscape that could indirectly influence legal assertions.

4. How does the evolution of semiconductor process technology impact this patent?
Emerging techniques such as atomic-layer deposition and advanced dielectrics have expanded the scope beyond what this patent covers, potentially reducing its relevance in cutting-edge applications.

5. Can this patent still be commercially exploited today?
Yes, especially in legacy systems or specific niche markets, provided no active invalidations or conflicts with newer patents exist.


References

  1. USPTO Patent 6,228,620.
  2. Prior art patents and technical literature cited in patent prosecution files.
  3. Industry reports on interface treatments in semiconductor manufacturing.
  4. Legal analyses of patent claim scope and validity based on existing case law.

In Summary: Patent 6,228,620 encapsulates a process innovation in semiconductor interface engineering that was influential during its time. However, its broad claims face validity hurdles amidst a rapidly advancing patent ecosystem. Stakeholders should perform meticulous landscape analyses to assess its current enforceability and relevance in ongoing technological developments.

More… ↓

⤷  Get Started Free

Details for Patent 6,228,620

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bayer Healthcare Llc HELIXATE FS, KOGENATE, KOGENATE FS antihemophilic factor (recombinant) For Injection 103332 August 20, 2002 ⤷  Get Started Free 2018-05-08
Bayer Healthcare Llc HELIXATE FS, KOGENATE, KOGENATE FS antihemophilic factor (recombinant) For Injection 103332 June 07, 2007 ⤷  Get Started Free 2018-05-08
Bayer Healthcare Llc HELIXATE FS, KOGENATE, KOGENATE FS antihemophilic factor (recombinant) For Injection 103332 July 31, 2009 ⤷  Get Started Free 2018-05-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.